Logo

PanTherix, Genome Therapeutics Collaborate on Protein Structure Analysis for Drug Targets

Jan 23, 2003

NEW YORK, Jan. 23 - PanTherix and Genome Therapeutics said today they have entered a research collaboration in the search for drug targets.

 

Genome Therapeutics will use PanTherix's protein structure determination technology to unlock the three-dimensional structures of its bacterial targets in its anti-infective drug discovery program, the company said.

 

Financial terms of the agreement were not disclosed.

 

Click here for more information.

 

 

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.